Key Research

By developing and patenting the first predictive thera-nostic biomarker profile in the field of Multiple Myeloma we have opened the door to personalising patient therapies to maximise patient response rates to treatment of all Blood Diseases
Through our research we have opened up the possibility of treating patients individually rather than the current “one size fits all” approach. Better response rates, avoidance of ineffective therapy and disease and therapyrelated complications, could greatly improve patient quality of life, reduce costs to healthcare providers, and impact on survival.

Our laboratory partners are based at the National Institute for Bioprocessing Research & Technology(NIBRT) and the Department of Biology at Maynooth University. We have world-class facilities for nanotechnology and bioprocessing, including proteomic, glycobiology labs and molecular biology labs. We have state of the art molecular proteomic instrumentation and advanced core
instruments for glycan analysis including

• FPLC/HPLC with fraction collector and on-line absorbance measurement systems

• High-performance liquid chromatography (HPLC)

• Extensive mass spectrometry platforms including MALDI-TOF, ESI-MS, Agilent LC-MS 6340 ETD mass spectrometer, Ettan MALDI-ToF mass spectrometer, Thermo Q-Exactive mass spectrometer

• Capillary electrophoresis laser induced fluorescent (CE-LIF),

• Glycobioinformatics for glycan profiling,

• Advanced microscopy for the investigation of dynamic processes of living cells

• Fluorescent image analysis system.

• Spectrophotometer-fluorimeter-96-well plate reader.

• 96-well plate reader for scintillation and luminescence.

• SDS-PAGE, 2D-PAGE and Western blotting apparatus.

• Cell culture facility with regular quality control of cell viability.